125 related articles for article (PubMed ID: 20501616)
41. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
42. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
[TBL] [Abstract][Full Text] [Related]
43. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
O'Connor OA; Horwitz S; Hamlin P; Portlock C; Moskowitz CH; Sarasohn D; Neylon E; Mastrella J; Hamelers R; Macgregor-Cortelli B; Patterson M; Seshan VE; Sirotnak F; Fleisher M; Mould DR; Saunders M; Zelenetz AD
J Clin Oncol; 2009 Sep; 27(26):4357-64. PubMed ID: 19652067
[TBL] [Abstract][Full Text] [Related]
44. Pralatrexate, a new hope for aggressive T-cell lymphomas?
Rueda A; Casanova M; Quero C; Medina-Pérez A
Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
[TBL] [Abstract][Full Text] [Related]
45. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Shen L; Au WY; Guo T; Wong KY; Wong ML; Tsuchiyama J; Yuen PW; Kwong YL; Liang RH; Srivastava G
Blood; 2007 Jul; 110(1):469-70. PubMed ID: 17579189
[No Abstract] [Full Text] [Related]
46. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Serova M; Bieche I; Sablin MP; Pronk GJ; Vidaud M; Cvitkovic E; Faivre S; Raymond E
Br J Cancer; 2011 Jan; 104(2):272-80. PubMed ID: 21179031
[TBL] [Abstract][Full Text] [Related]
47. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
O'Connor OA; Hamlin PA; Portlock C; Moskowitz CH; Noy A; Straus DJ; Macgregor-Cortelli B; Neylon E; Sarasohn D; Dumetrescu O; Mould DR; Fleischer M; Zelenetz AD; Sirotnak F; Horwitz S
Br J Haematol; 2007 Nov; 139(3):425-8. PubMed ID: 17910632
[TBL] [Abstract][Full Text] [Related]
48. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Jennifer C Z; Sara Mohamed J; Salma A; Francine F
Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
[TBL] [Abstract][Full Text] [Related]
49. Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
Oiwa K; Hosono N; Nishi R; Scotto L; O'Connor OA; Yamauchi T
BMC Cancer; 2021 Jul; 21(1):879. PubMed ID: 34332580
[TBL] [Abstract][Full Text] [Related]
50. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
Marneros AG; Grossman ME; Silvers DN; Husain S; Nuovo GJ; MacGregor-Cortelli B; Neylon E; Patterson M; O'Connor OA; Zain JM
Blood; 2009 Jun; 113(25):6338-41. PubMed ID: 19389878
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Marchi E; O'Connor OA
Ther Adv Hematol; 2012 Aug; 3(4):227-35. PubMed ID: 23606933
[TBL] [Abstract][Full Text] [Related]
52. Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial.
Park S; Kim AY; Cho H; Baik D; Lee H; Cho S; Kang HY
BMC Cancer; 2020 Nov; 20(1):1157. PubMed ID: 33243162
[TBL] [Abstract][Full Text] [Related]
53. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
Bhurani M; Admojo L; Van Der Weyden C; Twigger R; Bazargan A; Quach H; Zimet A; Coyle L; Lindsay J; Radeski D; Hawkes E; Kennedy G; Irving I; Gutta N; Trotman J; Yeung J; Dunlop L; Hua M; Giri P; Yuen S; Panicker S; Moreton S; Khoo L; Scott A; Kipp D; McQuillan A; McCormack C; Dickinson M; Prince HM
Leuk Lymphoma; 2021 Feb; 62(2):330-336. PubMed ID: 33026266
[TBL] [Abstract][Full Text] [Related]
54. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
O'Connor OA; Amengual J; Colbourn D; Deng C; Sawas A
Leuk Lymphoma; 2017 Nov; 58(11):2548-2557. PubMed ID: 28738754
[TBL] [Abstract][Full Text] [Related]
55. Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome.
Ware O; Tarabadkar ES; Shustov A; Shinohara MM
J Am Acad Dermatol; 2020 Feb; 82(2):489-491. PubMed ID: 31319088
[No Abstract] [Full Text] [Related]
56. [Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma].
Sawada K; Sata H; Yasumi M; Karasuno T
Gan To Kagaku Ryoho; 2020 Jan; 47(1):95-97. PubMed ID: 32381871
[TBL] [Abstract][Full Text] [Related]
57. Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers.
Scotto L; Kinahan C; Casadei B; Mangone M; Douglass E; Murty VV; Marchi E; Ma H; George C; Montanari F; Califano A; O'Connor OA
Genes Chromosomes Cancer; 2020 Nov; 59(11):639-651. PubMed ID: 32614991
[TBL] [Abstract][Full Text] [Related]
58. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.
Tedeschi PM; Kathari YK; Johnson-Farley N; Bertino JR
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1247-52. PubMed ID: 25917288
[TBL] [Abstract][Full Text] [Related]
59. Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.
Sinan Dal M; Merdin A; Erkurt MA; Ekinci Ö; Albayrak M; Kabukcu Hacıoglu S; Kaya A; Dogu MH; Hindilerden F; Sarici A; Merter M; Reis Aras M; Akgun Caglıyan G; Kizil Cakar M; Aydogdu I; Kuku I; Korkmaz S; Ulas T; Eser B; Altuntas F
J BUON; 2021; 26(4):1536-1539. PubMed ID: 34565016
[TBL] [Abstract][Full Text] [Related]
60. Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.
Casanova M; Medina-Pérez A; Moreno-Beltran M; Mata-Vazquez M; Rueda A
Ther Clin Risk Manag; 2011; 7():401-8. PubMed ID: 22076116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
